Abstract
In 2011, cell-free fetal DNA (cffDNA or cfDNA) screening for fetal aneuploidy became clinically available in the United States. At first recommended only for high-risk obstetric populations, cell-free DNA has more recently been made available to the general (low-risk) obstetric population. Extending this screening test to the general population raises multiple ethical issues. The complexity of the genetic information revealed by testing coupled with the practical challenge of counseling greater numbers of patients may undermine the possibility of genuine informed consent.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical Ethics at the Crossroads of Genetic and Reproductive Technologies
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
